Figure 9

Effects of p38 MAPK and ERK-1,2 inhibitors on hMSC adhesion to HUVECs treated with vWF. HUVECs were pre-incubated with p38 MAPK inhibitor SB203580 (10 μM), its inactive analog SB202474 (10 μM) or the inhibitors of ERK-1,2 phosphorylation, PD98059 (10 μM) or U0126 (10 μM), for 45 minutes and treated with 4 μg/ml vWF for four hours in the presence of the protein kinase inhibitors. (a) Shows the effects of the protein kinase inhibitors on hMSC adhesion to HUVECs treated with and without vWF. Data are shown as mean ± SD of eight independent measurements. Single asterisks mark statistically significant changes in hMSC adhesion in comparison with HUVECs not treated with vWF (t-test, P-value <0.05). Treatment of HUVECs with vWF in the presence of SB203580 resulted in the inhibition of hMSC adhesion in comparison with hMSC adhesion to HUVECs treated with vWF alone (double asterisks, t-test, P-value <0.05) or in comparison with hMSC adhesion to HUVECs treated with vWF in the presence of SB202474 (pound key, t-test, P-value <0.05). (b) Shows the dose-dependent effect of SB203580 (0 to 20 μM) on hMSC adhesion to HUVECs treated with (white circle) and without (black circle) vWF. Data are shown as mean ± SD of eight independent measurements. Asterisks mark data point with statistically significant difference from HUVECs maintained in HBSS.